Hi Slum, I haven't posted for a while, but have been in SGEN since January 2007 (had to look that up). This is what you want in a biotech, a drug that works, minimal dilution, strong pipeline and potential royalties from partnerships, we have them all....I bought GILD early on, but unfortunately had a very small # of shares, this time I'm much more "loaded up". I've also had flame outs, won't deny that, but that's what happens in biotech....I'm not selling here as I see the business model leading to long term gains, potentially significant, even from here. Too bad Rick seems to have left us permanently with his 10 is 10 bs., my buy and hold strategy has suited me just fine!
EOY is just a WAG but depending on how much of the over 60 HL progress can be shown $60 is plausible .
Beyond that we really need to look out 3-4 years when the 20 or so current trials are mostly complete. In that time frame if even 50% are successfull adding up revenues from proprietary and royalties from the partners, SGEN will have grown into a big pharma power house with a market cap north of $ 25 billions (i.e. $200 + per share).
I'm a wild eyed optimis but just like a broken clock I get it right once in a while too.